

Sponsor	Short title, Title	Clinical Trial Database number, Eudract/EU CT	Drug/substance and vector (if applicable)	Trial Phase	Trial Status	Disease Area	Indication	ATMP class	Cell Type	Gene Therapy	Autologous/Allogeneic	Site(s) in Sweden	Start Year
Novartis	Cassiopeia. A Phase II trial of tisagenlecleucel in first-line high-risk (HR) pediatric and young adult patients with B-cell acute lymphoblastic leukemia (B-ALL) who are minimal residual disease (MRD) positive at the end of consolidation (EOC) therapy.	NCT03876769 2023-508081-15-00	CTL019, Kymriah	II	In follow-up	Paediatric oncology	Paediatric and young adult patients with B-cell acute lymphoblastic leukemia (B-ALL)	GTMP	T cells	Yes, ex vivo	Autologous	Karolinska University Hospital, Stockholm Sahlgrenska University Hospital, Göteborg	2021
Janssen-Cilag	CARTITUDE-5. A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleucl, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants with Newly Diagnosed Multiple Myeloma for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy.	NCT04923893 2021-001242-35	Ciltacabtagene Autoleucl (cilta-cel) lentiviral vector	III	In follow-up	Oncology	multiple myeloma	GTMP	T cells	Yes, ex vivo	Autologous	Linköping University Hospital, Linköping Sahlgrenska University Hospital, Göteborg Skåne University Hospital, Lund	2022
AlloVir	VIR303. Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial, With Cross-Over, of Posoleucl (ALVR105) for the Treatment of Adenovirus Infection in Pediatric and Adult Participants Receiving Standard of Care Following Allogeneic Hematopoietic Cell Transplantation.	NCT05179057 2021-003450-22	Posoleucl	III	Completed	Paediatrics - adenovirus infection after allogeneic transplantation	Adenovirus Infection after allogeneic transplantation	sCTMP	Multi-virus specific T cell therapy; Virus infected previously in hematopoietic cell transplanted patients	No	Allogeneic	Karolinska University Hospital, Stockholm Sahlgrenska University Hospital, Göteborg Skåne University Hospital, Lund	2022
Sarepta therapeutics	ENVISION. A Phase 3, Multinational, Randomized, Double-Blind, Placebo-Controlled Systemic Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of SRP-9001 in Non-Ambulatory and Ambulatory Subjects With Duchenne Muscular Dystrophy.	2020-002372-13	SRP-9001, Delandistrogene moxeparovvec rAAVrh74 containing human micro-dystrophin gene	III	Recruiting	Pediatric neurology	Non-Ambulatory and Ambulatory Subjects With Duchenne Muscular Dystrophy	GTMP	N/A	Yes, in vivo		Sahlgrenska University Hospital, Göteborg Karolinska University Hospital, Stockholm	2022
BioNTech SE	An open label Phase II randomized trial of BNT113 in combination with pembrolizumab versus pembrolizumab monotherapy as a first line therapy in patients with unresectable recurrent, or metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) which is positive for human papilloma virus 16 (HPV16+) and expresses PD-L1	NCT04534205 2020-001400-41	BNT113	II	Completed	Oncology	unresectable recurrent, or metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) which is positive for human papilloma virus 16 (HPV16+) and expresses PD-L1	GTMP	N/A	Yes, in vivo		Sahlgrenska University Hospital, Göteborg Skåne University Hospital, Lund	2022
Göteborg University	HAITILS. A Phase I Study Using Hepatic Arterial Infusion of Autologous Tumor Infiltrating Lymphocytes in Patients With Melanoma and Liver Metastases.	NCT04812470 2020-006126-31	Autologous Tumor Infiltrating Lymphocytes	I	In follow-up	Oncology - melanoma	Patients with melanoma and liver metastases		Tumor Infiltrating Lymphocytes		Autologous	Sahlgrenska University Hospital, Göteborg	2023
Merck Sharp & Dohme LLC	A Phase 3, Randomized, Double-Blind, Placebo- and Active- Comparator-Controlled Clinical study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With High-Risk Stage II-IV Melanoma.	NCT05933577 2023-503652-27-00	mRNA-4157 (V940) liposomally formulated mRNA.	III	In follow-up	Oncology	Malignant melanoma	GTMP	N/A	Yes, in vivo		Sahlgrenska University Hospital, Göteborg Skåne University Hospital, Lund	2023
Xintela	XIN-XSTEM-201. A single-centre, randomised, single-blind Phase I/IIa study to evaluate the safety, tolerability and efficacy of a single topical dose of allogeneic integrin $\alpha 10\beta 1$ -selected mesenchymal stem cells (XSTEM-VLU) in patients with difficult-to-heal venous leg ulcers.	NCT05549609 2022-000492-39	XSTEM-VLU	I/II	Completed	Skin. Chronic wounds	Venous leg ulcers	sCTMP	Integrin $\alpha 10\beta 1$ -selected mesenchymal stem cells	No	Allogeneic	Sahlgrenska University Hospital, Göteborg Skåne University Hospital, Lund	2023
European Myeloma Network	CARTITUDE-6. A Phase 3 Randomized Study Comparing Daratumumab, Bortezomib, Lenalidomide and (DVRd) followed by Ciltacabtagene Autoleucl versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Autologous Stem Cell Transplant (ASCT) in Participants with Newly Diagnosed Multiple Myeloma who are Transplant Eligible.	NCT05257083 2021-003284-10/ 2023-507632-20-00	Ciltacabtagene Autoleucl (cilta-cel) lentiviral vector	III	In follow-up	Oncology	multiple myeloma	GTMP	CAR T cells	Yes, ex vivo	Autologous	Linköping University Hospital, Linköping Sahlgrenska University Hospital, Göteborg Skåne University Hospital, Lund. Uppsala University Hospital, Uppsala	2023
Iovance Biotherapeutics	A Phase 3, multicenter, randomized, open-label, parallel group, treatment study to assess the efficacy and safety of the lifileucl (LN-144, autologous tumor-infiltrating lymphocytes [TIL]) regimen in combination with pembrolizumab compared with pembrolizumab monotherapy in participants with untreated, unresectable or metastatic melanoma.	NCT05727904 2022-503140-41-00	Lifileucl (LN-144)	III	Recruiting	Oncology	untreated, unresectable or metastatic melanoma	sCTMP	TILs	No	Autologous	Sahlgrenska University Hospital, Göteborg	2024
RHEACELL	A pivotal, randomized, placebo-controlled, double-blind, multicenter, international phase III clinical trial to investigate the efficacy and safety of allo-AP22-CVU on wound healing of therapy-resistant non-healing chronic venous ulcers (CVU).	NCT06489028 2024-512720-11	allo-AP22-CVU	III	In follow-up	Skin and subcutaneous tissue disorders	Therapy-resistant non-healing chronic venous ulcers (CVU)	sCTMP	Mesenchymal Stromal Cells	No	Allogeneic	Academic primary care center, Uppsala Sahlgrenska University Hospital, Göteborg	2025
Genentech, Inc.	IMCCODE003 (GO44479), A Phase II, open-label, Multicenter, Randomized study of the efficacy and safety of adjuvant autogene cevumeran plus atezolizumab and mFFN vs mFFN alone in patients with resected pancreatic ductal adenocarcinoma	2022-502404-73-00	autogene cevumeran	II	Recruiting	Oncology	Pancreatic adenocarcinoma	GTMP		Yes, in vivo	Allogeneic	Sahlgrenska University Hospital, Göteborg	2025
Roche	IMCCODE004A randomized phase II, double-blind, multicenter study of autogene cevumeran plus nivolumab versus placebo plus nivolumab as adjuvant therapy in patients with high-risk muscle-invasive urothelial carcinoma	2023-509023-40-00	autogene cevumeran	II	Recruiting	Oncology	urothelial carcinoma	GTMP		Yes, in vivo	Allogeneic	Sahlgrenska University Hospital, Göteborg	2025
University Hospital Basel	Randomized, controlled, multi-center phase II clinical trial for the treatment of patellofemoral osteoarthritis with nasal chondrocyte-based tissue engineered cartilage implantation vs current standard of care	2024-513683-25-00	N-TEC	II	Recruiting	Rheumatology	patellofemoral osteoarthritis	cATMP	chondrocytes	No	Autologous	Sahlgrenska University Hospital, Göteborg	2026
Celgene Corp.	A Phase 3 Study of a GPRCSD-directed CAR T Cell Therapy in Participants with Relapsed or Refractory Multiple Myeloma and Exposed to Lenalidomide	2024-515279-37-00	arlo-cel	III	Recruiting	Haematology	Multiple Myeloma	GTMP	CAR-T	Yes, ex vivo	Autologous	Sahlgrenska University Hospital, Göteborg	2026